Capital Expenditures for Biogen (BIIB)
According to Biogen's latest reported financial statements, the company's current capital expenditures (TTM) is $153.80M USD. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
BIIB
Currently viewingCapital ExpendituresSwitch metric
Latest period
$153.80M
YoY change
-57.3%
5Y CAGR
-18.4%
Peak year (2013)
$3.51B
Cumulative capital expenditures
$12.47B
CapEx history chart for Biogen (BIIB) from 1989 to 2025
CapEx history table for Biogen (BIIB) from 1989 to 2025
| Fiscal year | Period ended | Reported | Capital Expenditures | YoY |
|---|---|---|---|---|
| 2025 | $153.80M | -57.3% | ||
| 2024 | $359.80M | +15.5% | ||
| 2023 | $311.40M | +29.6% | ||
| 2022 | $240.30M | -6.9% | ||
| 2021 | $258.10M | -39.2% | ||
| 2020 | $424.80M | -17.4% | ||
| 2019 | $514.50M | -33.2% | ||
| 2018 | $770.60M | -11.2% | ||
| 2017 | $867.40M | +40.8% | ||
| 2016 | $616.10M | -4.2% | ||
| 2015 | $643.00M | +123.4% | ||
| 2014 | $287.80M | -91.8% | ||
| 2013 | $3.51B | +1278.5% | ||
| 2012 | $254.55M | +0.9% | ||
| 2011 | $252.18M | +45.7% | ||
| 2010 | $173.06M | +4.5% | ||
| 2009 | $165.65M | -40.0% | ||
| 2008 | $275.95M | -2.9% | ||
| 2007 | $284.11M | +43.3% | ||
| 2006 | $198.31M | -37.7% | ||
| 2005 | $318.38M | -13.9% | ||
| 2004 | $369.76M | +22.7% | ||
| 2003 | $301.25M | +81.6% | ||
| 2002 | $165.90M | -15.2% | ||
| 2001 | $195.53M | -1.8% | ||
| 2000 | $199.12M | +130.7% | ||
| 1999 | $86.33M | +156.8% | ||
| 1998 | $33.61M | -5.5% | ||
| 1997 | $35.55M | -45.8% | ||
| 1996 | $65.64M | +30.5% | ||
| 1995 | $50.31M | +15.2% | ||
| 1994 | $43.67M | +304.4% | ||
| 1993 | $10.80M | +14.9% | ||
| 1992 | $9.40M | +11.9% | ||
| 1991 | $8.40M | -24.3% | ||
| 1990 | $11.10M | +258.1% | ||
| 1989 | $3.10M | — |
CapEx values are taken from Biogen's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, Biogen (BIIB) capital expenditures totalled $153.80M – plunged 57.3% year-over-year.
Biogen capital expenditures compound annual growth for the 2020–2025 (5 years) window is -18.4%, with a net decline across the window.
Biogen capital expenditures plunged from $3.51B in 2013 to $153.80M in 2025, a 95.6% drawdown.
2013 marks the peak capital expenditures at $3.51B, with the historical low of $3.10M recorded in 1989.
Among 8 Healthcare peers, Biogen (BIIB) ranks 9th; the peer median for capital expenditures is $3.87B.
Biogen Capital Expenditures by Year
Biogen Capital Expenditures 2025: $153.80M
Biogen capital expenditures in 2025 was $153.80M, plunged 57.3% below 2024.
Biogen Capital Expenditures 2024: $359.80M
Biogen capital expenditures in 2024 was $359.80M, grew 15.5% from 2023.
Biogen Capital Expenditures 2023: $311.40M
Biogen capital expenditures in 2023 was $311.40M, grew 29.6% from 2022.
Biogen Capital Expenditures 2022: $240.30M
Biogen capital expenditures in 2022 was $240.30M, declined 6.9% below 2021.
Biogen Capital Expenditures 2021: $258.10M
Biogen capital expenditures in 2021 was $258.10M.
See more financial history for Biogen (BIIB).
Sector peers — CapEx
Companies in the same sector as Biogen, ranked by their latest capital expenditures.
| Company | Capital Expenditures | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $90.11B | Healthcare |
| Eli Lilly and Company (LLY) | $7.84B | Healthcare |
| Johnson & Johnson (JNJ) | $4.83B | Healthcare |
| Merck & Co., Inc. (MRK) | $4.11B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $3.62B | Healthcare |
| AstraZeneca PLC (AZN) | $2.81B | Healthcare |
| Amgen Inc. (AMGN) | $1.86B | Healthcare |
| AbbVie Inc. (ABBV) | $1.21B | Healthcare |
Frequently asked questions
What is Biogen's capital expenditures?
- Latest reported capital expenditures for Biogen (BIIB) is $153.80M (period ending December 31, 2025).
How has Biogen capital expenditures changed year-over-year?
- Biogen (BIIB) capital expenditures changed -57.3% year-over-year on the latest annual filing.
What is the long-term growth rate of Biogen capital expenditures?
- Biogen (BIIB) capital expenditures compound annual growth rate is -18.4% over the most recent 5 years available.
When did Biogen capital expenditures hit its highest annual value?
- Biogen capital expenditures reached its highest annual value of $3.51B in 2013.
What was Biogen capital expenditures in 2024?
- Biogen (BIIB) capital expenditures in 2024 was $359.80M.
What was Biogen capital expenditures in 2025?
- Biogen (BIIB) capital expenditures in 2025 was $153.80M.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
BIIB Overview
Company profile, financial tools, and key metrics
BIIB Revenue Counter
Earns $311.09 every second. See per minute, hour, and day.
BIIB Earnings Counter
Earns $41.01 per second net profit. See per minute, hour, and day.
BIIB Economic Scale
Exceeds Bermuda's GDP. Compare with world economies.
BIIB What If Invested
What if you had invested $1,000? See historical returns from any date.
BIIB How It Makes Money
Discover visual breakdown of $9.81B in revenue — where it comes from and where it goes.
BIIB Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
BIIB Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
BIIB Daily Price Character
Explosive · 48.1% historical win rate (green days). Streaks & record days.
BIIB Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.
BIIB Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.